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Established Facts
• Already known fact 1: Deep penetrating nevus (DPN) is a well-established histopathological and mo-
lecular distinct nevus subtype of the skin. 
• Already known fact 2: Overlapping clinical and histopathological features might complicate distin-
guishing benign from malignant melanocytic lesions.
Novel Insights
• New information 1: Molecular analysis might be necessary in rendering a correct diagnosis; in this case, 
a DPN was confirmed by the presence of a β-catenin mutation with exclusion of molecular abnormal-
ities as found in melanoma. 
• New information 2: The presentation of a DPN of the lacrimal caruncle emphasizes the similarities of 
the caruncle with the skin.
DOI: 10.1159/000504966
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Abstract
We describe the first presentation of a deep penetrating ne-
vus (DPN) on the lacrimal caruncle. This lesion was seen in an 
18-year-old woman presenting with hemorrhage of a long-
standing pigmented mass on the caruncle. Histology showed 
a combined melanocytic neoplasm that consisted of two dif-
ferent melanocytic components. The differential diagnosis, 
based on histological examination, was a conventional me-
lanocytic nevus, a Spitz nevus, or a combined melanocytic 
nevus. On the molecular level, one of the components re-
vealed a mutation in the CTNNB1 gene encoding the 
β-catenin protein, while both components harbored a BRAF 
V600E mutation, without molecular features of a malignant 
melanocytic lesion. This presentation of a DPN of the lacri-
mal caruncle emphasizes the similarities of the caruncle with 
the skin. © 2020 The Author(s)
Published by S. Karger AG, Basel
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Introduction
Lesions located at the lacrimal caruncle are uncom-
mon, and the differential diagnosis includes many differ-
ent entities because the caruncle harbors both skin and 
conjunctival elements. Although the majority of lesions 
on this location is benign [1, 2], overlapping clinical and 
histopathological features make it challenging to distin-
guish the benign lesions from their malignant counter-
part [2–4]. Therefore, thorough histological examination 
and additional diagnostic techniques for adequate man-
agement are required.
Case Report
An 18-year-old Caucasian female was referred to The Rotter-
dam Eye Hospital, Rotterdam, The Netherlands, because of a bleed-
ing caruncular mass. She had a medical history of hyperpigmenta-
tion in the medial corner of the right eye for at least 6 years. On 
clinical examination, the caruncle of the right eye showed a 4-mm 
stalked slightly asymmetrical dome-shaped pigmented hyperemic 
mass with crust and large vessels in the stalk (Fig. 1a). Vision was 
1.20 for both eyes, with an intraocular pressure in the right eye and 
left eye of 16 mm Hg and 11 mm Hg, respectively. For both diag-
nostic and therapeutic reasons the lesion was excised. The clinical 
differential diagnosis included pigmented papilloma, melanocytic 
nevus, melanoma, pyogenic granuloma, and oncocytoma. 
Histological examination showed a papillomatous, partly pig-
mented melanocytic lesion with a junctional as well as a stromal 
component. The lesion was composed of two different compo-
nents: one of which revealed a more nevoid character, with cells 
with scant amphophilic cytoplasm and a small hyperchromatic 
nucleus, and the other component showed a more epithelioid mor-
phology, with cells with large dusty cytoplasm and a small, slightly 
irregular nucleus arranged in nests and fascicles (Fig. 1b, c). More-
over, perifollicular extension was found. There was no obvious cy-
tological atypia, yet one mitotic figure was seen in the stromal part 
of the lesion. The conventional nevoid component showed matu-
ration, in contrast to the epithelioid component. Furthermore, as-
sociated melanophages were seen. Using immunohistochemistry, 
both components showed diffuse expression of Melan A. HMB-45 
showed loss of expression in the nevoid component, while expres-
sion remained in the epithelioid component (Fig. 1f). Both com-
ponents showed positivity for BRAF V600E (Fig. 1g) and no loss 
of expression of BAP1 or p16. Staining for β-catenin (Fig.  1d) 
showed, mainly in the epithelioid component and to a lesser extent 
in the nevoid component in both the upper as well as the lower part 
of the lesion, extensive cytoplasmic and membranous expression, 
but no nuclear expression. Additionally, Cyclin D1 (Fig.  1e) 
showed a strong nuclear staining in the epithelioid component, 
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Fig. 1. Macroscopic view, H&E and immunohistochemical stain-
ing of the DPN. Photograph demonstrating a 4-mm slightly asym-
metrical dome-shaped pigmented lesion located on the caruncle 
(a). The H&E staining shows both the nevoid component (upper 
part) and the epithelioid component (lower part) at magnifications 
of 5× (b) and 20× (c), with the black and red arrow demonstrating 
the nevoid component and the epithelioid component, respective-
ly. The epithelioid component is arranged in compact nests of cells 
with large dusty cytoplasm and small, slightly irregular nucleus. 
These nests show some pigmentation. In contrast, the nevoid com-
ponent consists of loosely arranged clusters of cells with scant am-
phophilic cytoplasm and a small hyperchromatic nucleus. The im-
munohistochemical stainings show absence of nuclear expression 
of β-catenin (magnification 10×, with a magnification of 40× in the 
upper right corner; d), strong nuclear expression in the epithelioid 
component, and absent to weak expression of Cyclin D1 in the 
deeper parts of the nevoid component (magnification 5×, with a 
magnification of 40× in the upper right corner; e), and dark stain-
ing of the epithelioid component in contrast to the nevoid compo-
nent in the HMB-45 staining (magnification 5×; f). Both compo-
nents show immunohistochemical expression of BRAF V600E 
(magnification 10×; g). 
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with an absent to weak staining in the deep parts of the nevoid 
component. Triple fluorescence in situ hybridization showed no 
abnormalities for CCND1, MYB, and RREB1. 
The two components of the lesion were isolated from the forma-
lin-fixed paraffin-embedded material and were analyzed separately 
for molecular analysis. Both components showed a mutation in 
BRAF exon 15:c.1799 T>A; p.V600E, using mutation-specific PCR. 
Furthermore, targeted next-generation sequencing analysis con-
firmed this BRAF mutation and revealed a mutation in CTNNB1 
exon 3:c.134 C>T; p.S45F in the epithelioid component in contrast to 
the conventional nevoid component (Fig. 2). There were no GNA11, 
GNAQ, GNAS, HRAS, NRAS, APC, MAP2K1, and TERT promoter 
mutations, and there was no loss of CDKN2A. No additional copy 
number variations were identified by SNP array. Altogether, these 
findings are consistent with a deep penetrating nevus (DPN). 
Discussion/Conclusion
Lesions located on the lacrimal caruncle are rare, with 
10% comprising (pre-)malignant lesions. Over 40% of the 
lesions that present on the caruncle are pigmented [2]. 
Although the majority of the pigmented lesions are con-
ventional melanocytic nevi [1, 2], the (pre-) malignant 
melanocytic lesions warrant special attention. Distin-
guishing benign lesions from their malignant counterpart 
can be very challenging [2–4], both from a clinical and 
histological point of view, because of various overlapping 
features. The caruncle comprises both skin and conjunc-
tival elements. Therefore, lesions of both tissue types 
must be considered in the differential diagnosis. In the 
skin, melanocytic lesions comprise a broad differential 
diagnosis, including a conventional melanocytic nevus 
[5], a blue nevus, a Spitz nevus, a DPN, and melanoma. 
[5, 6]. The difference between melanoma and a DPN can 
be very challenging as both may share worrisome features 
including cytological atypia, mitotic figures in the deeper 
parts of the lesion, and absent maturation. Furthermore, 
a DPN may show perineural extension. Yet, in contrast to 
melanoma, in DPN, recurrences are uncommon [4] and 
these lesions rarely show malignant transformation [4, 7]. 
This emphasizes the need for additional techniques, in-
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Fig. 2. Targeted next-generation sequencing concerning muta-
tions in the BRAF and CTNNB1 gene. Targeted next-generation 
sequencing analysis revealed a missense mutation in the BRAF 
gene, comprising a substitution at codon 600 (NM_004333; c.1799 
T>A), resulting in a change from amino acid valine (V) to glutam-
ic acid (E) (p.V600E) in both the nevoid component and the epi-
thelioid component (a, c, respectively). In contrast to the nevoid 
component (b), the epithelioid component (d) also harbored a 
missense mutation in the CTNNB1 gene encoding the β-catenin 
protein, comprising a substitution at codon 45 (NM_001098209; 
c.134 C>T), resulting in a change from amino acid serine (S) to 
phenylalanine (F) (p.S45F). Ref, reference; seq, sequence; comb, 
combined; F, forward; R, reverse; Cov, coverage.
Co
lor
 ve
rsi
on
 av
ail
ab
le 
on
lin
e
van Ipenburg/Damman/Paridaens/
Verdijk
Ocul Oncol Pathol4
DOI: 10.1159/000504966
cluding immunohistochemistry and molecular analysis, 
for further characterization. 
The current lesion harbored two different components 
with presence of a mitotic figure in the stromal part of the 
lesion and one of the components lacking maturation, 
without loss of staining intensity in the HMB-45 staining 
towards the deeper parts of the lesion. Additional to these 
worrying features, both components harbored a BRAF 
mutation, which may occur in both skin and conjunctival 
melanoma [7, 8]. In this perspective, β-catenin, with direct 
transcriptional target cyclin D1 [9], is of interest, which 
plays an important role in both the MAPK pathway [7] 
and the Wnt pathway [3]. A β-catenin mutation is absent 
in conventional nevi, but is present in DPNs [7]. Although 
this mutation is also found in DPN-like melanoma, both 
skin and conjunctival melanoma harbor TERT mutations 
[7, 10]. Moreover (DPN-like) skin melanomas are report-
ed to also harbor TP53 and BAP1 mutations, as well as 
biallelic loss of CDKN2A, in contrast to DPN without ma-
lignant behavior [7]. Since these mutations were not de-
tected in our case, the diagnosis of DPN is confirmed.
In conclusion, this is the first description, including 
molecular characterization, of a DPN located on the lac-
rimal caruncle. Because of the unique composition of the 
caruncle, there is a broad differential diagnosis regarding 
pigmented lesions. As these lesions may be very difficult 
to discriminate by clinical and histological examination 
only, additional molecular analysis might be necessary in 
rendering a correct diagnosis. Furthermore, this first pre-
sentation of a DPN of the lacrimal caruncle emphasizes 
the similarities of the caruncle with the skin. 
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